Navigation Links
Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
Date:11/6/2008

significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognises the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavour.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Aposense Ltd.

Aposense Ltd. is a molecular imaging and drug development company, leading the translation of the science of apoptosis (programmed cell death) into clinical practice. Aposense introduces novel imaging and therapeutic agents based on rationally-designed, nano-mechanisms for selective targeting of cells undergoing apoptosis. Aposense technology is based on a new, patented class of small molecular probes that selectively identify and accumulate within apoptotic (dying) cells in vivo. Apoptosis plays a role in many diseases across numerous clinical areas, including oncology, neurology and cardiology. Aposense probes for Molecular Imaging enable real-time visualization of the biological activity of disease, its onset, change in course and response to therapy, and to personalize treatment for the individual patient in cancer and other diseases. Therapeutic applications of Aposense technology in pre-clinical development include anticancer therapy which uses apoptotic cells in tumors as targets for specific delivery of cytotoxic compounds into the tumor. For additional information, visit http://www.aposense.com

About Frost & Sullivan


'/>"/>

SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... the scientific journal, Expert Opinion on Biological Therapy ... Dr. Zhenggang Zhang , at the Henry Ford ... that Thymosin beta 4 (TB4) has the capacity to ... hours or more post-injury, leading to neurological recovery in ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the ... under Chapter 11 of the U.S. Bankruptcy Code in the ... , Santa Ana division (the "Bankruptcy ... are expected to be jointly administered. The Company ... sale process, for all or substantially all of its assets ...
(Date:3/3/2015)... 2015 Genedata, a leading provider ... life science research, today announced that Pfizer Inc. ... for use at Pfizer biopharma research and development ... supporting Pfizer’s global deployment and roll out project ... Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups. ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3
... recombinant attenuated Salmonella vaccines (RASV), holds great ... B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia. ... Institute at Arizona State University, have developed a technique ... group, under the direction of Dr. Roy Curtiss, chief ...
... special issue of Physics World, which examines the science and ... College London describe a new type of invisibility cloak that ... the ultimate bank heist as an example, McCall and Kinsler ... cloak" to steal money from a safe, without even the ...
... 30, 2011 Dendreon Corporation (Nasdaq: ... broad availability for on-label use of PROVENGE® (sipuleucel-T), ... of asymptomatic or minimally symptomatic metastatic castrate resistant ... The U.S. Food and Drug Administration ...
Cached Biology Technology:New salmonella-based 'clean vaccines' aid the fight against infectious disease 2New salmonella-based 'clean vaccines' aid the fight against infectious disease 3Why 'event cloaks' could be the key to the ultimate bank heist 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)...  Businesses have a new option for premier ... Enterprises has announced the launch of a brand ... businesses to protect their customers, personal data, as ... Beconux is a biometric transaction processing system recently ... an ATM machine, the new system fuses multiple ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Personal Data Protection Company Launches New Product 2
... Scientists are another step closer to understanding what drives ... inside tumors that can slow their own growth. ... a journal of the American Association for Cancer Research, ... division of experimental medicine at the National Academy of ...
... preclinical studies in a skin cancer model showed ... BRAF inhibitors used in combination with an epidermal ... to prevent drug-induced skin lesions in BRAF mutation-positive ... presented at the AACR-NCI-EORTC International Conference: Molecular Targets ...
... Md. Increases in air pollution and other particulate matter ... that reduce precipitation in dry regions or seasons, while increasing ... regions or seasons, says a new study by a University ... the first clear evidence of how aerosols -- soot, dust ...
Cached Biology News:New approaches may prevent certain side effects in BRAF mutation-positive melanoma 2Rising air pollution worsens drought, flooding, UMD-led study shows 2Rising air pollution worsens drought, flooding, UMD-led study shows 3Rising air pollution worsens drought, flooding, UMD-led study shows 4
... FLIM system combines the space and time dimensions ... of the optical microscope to open new horizons ... light source for excitation, the decay of a ... of the decay measured. Subtle changes in ...
... 50 assays. The TUNEL-based assay kit provides ... cells for convenient detection of DNA fragmentation ... assay offers an one-step labeling of apoptotic ... a hallmark of apoptosis in mammalian cells. ...
... ScriptCap™ m7G Capping system ... and all of the components ... 0 on the end of ... These kits feature high efficiency ...
SDS-OutT Precipitation Reagent...
Biology Products: